<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198767</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066B2203</org_study_id>
    <nct_id>NCT03198767</nct_id>
  </id_info>
  <brief_title>Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066</brief_title>
  <official_title>A Randomized, Open Label, Two-part, Three-period, Cross Over Study to Investigate the Effects of Carbohydrate in Diet and to Evaluate Supplements on the Gastrointestinal Tolerability of LIK066 in Overweight or Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine if LIK066 taken with a meal containing low
      carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to
      assess the potential effects of supplements such as psyllium or calcium carbonate on
      alleviating diarrhea associated with LIK066.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Actual">September 4, 2017</completion_date>
  <primary_completion_date type="Actual">September 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Episodes of Diarrhea (Part A and Part B)</measure>
    <time_frame>24 hours on Day 3 of each treatment period</time_frame>
    <description>Episodes of diarrhea is defined as the total number of stools with a Bristol Stool Chart (BSC) Score of 6 or 7 on day 3 of each treatment period. BSC is frequently used as a measure of consistency, and a score of 6 or 7 (pourable or watery stool) is considered abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Three-day Total Number of Episodes of Diarrhea (Part A and Part B)</measure>
    <time_frame>Day 1 to 3 of each treatment period</time_frame>
    <description>Episodes of diarrhea is defined as the total number of stools with a Bristol Stool Chart (BSC) Score of 6 or 7 on days 1 to 3 of each treatment period. BSC is frequently used as a measure of consistency, and a score of 6 or 7 (pourable or watery stool) is considered abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Consistency With Bristol Stool Chart (Part A and Part B)</measure>
    <time_frame>24 hours on Day 3 of each treatment period</time_frame>
    <description>BSC is frequently used as a measure of consistency, ranging from score 1 (hard lumps) to 7 (watery stool).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Stool pH (Part A and Part B)</measure>
    <time_frame>24 hours on Day 3 of each treatment period</time_frame>
    <description>Average PH of Stool at day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Stool Weight (Part A and Part B)</measure>
    <time_frame>24 hours on Day 3 of each treatment period</time_frame>
    <description>24 hour average stool weight on day 3</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LIK066 + P1: 8% CHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 50 mg tablets. Open-label, bulk, blister-pack.</description>
    <arm_group_label>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 8% CHO</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate 50%</intervention_name>
    <description>50% carbohydrate in breakfast meal</description>
    <arm_group_label>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate 25%</intervention_name>
    <description>25% carbohydrate in breakfast meal</description>
    <arm_group_label>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate 8%</intervention_name>
    <description>8% carbohydrate in breakfast meal</description>
    <arm_group_label>Part A: LIK066 + P1: 8% CHO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate 0%</intervention_name>
    <description>0% carbohydrate in breakfast meal</description>
    <arm_group_label>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</arm_group_label>
    <arm_group_label>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Psyllium</intervention_name>
    <description>Powder 6 grams</description>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</arm_group_label>
    <other_name>MetaMucil®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>Liquid 1 gram (4 mL equivalent sugar free)</description>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</arm_group_label>
    <arm_group_label>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</arm_group_label>
    <other_name>Quality Value®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obese and overweight, BMI 25-50, HbA1C &lt;10%

        Exclusion Criteria:

          -  Preexisting, clinically significant cardiovascular, liver, renal, or GI disease that
             is considered unstable; pregnancy, Type 1 diabetes; Other protocol-defined
             inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <results_first_submitted>August 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2018</results_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>overweight</keyword>
  <keyword>body mass index</keyword>
  <keyword>BMI</keyword>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Psyllium</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03198767/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03198767/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 116 subjects were screened and 54 subjects were enrolled and randomized, with 48 completing the study. 6 subjects in Part A were discontinued due to a protocol deviation after day 3 dosing (the protein drink provided to subjects was incorrect and included 8% carbohydrate).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate</description>
        </group>
        <group group_id="P2">
          <title>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate</description>
        </group>
        <group group_id="P3">
          <title>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate</description>
        </group>
        <group group_id="P4">
          <title>Part A: LIK066 + P1: 8% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.</description>
        </group>
        <group group_id="P5">
          <title>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
        </group>
        <group group_id="P6">
          <title>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
        </group>
        <group group_id="P7">
          <title>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set. All subjects that received any study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate</description>
        </group>
        <group group_id="B2">
          <title>Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate</description>
        </group>
        <group group_id="B3">
          <title>Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate</description>
        </group>
        <group group_id="B4">
          <title>Part A: LIK066 + P1: 8% CHO</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.</description>
        </group>
        <group group_id="B5">
          <title>Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
        </group>
        <group group_id="B6">
          <title>Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
        </group>
        <group group_id="B7">
          <title>Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS</title>
          <description>Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Safety Analysis Set</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" lower_limit="21" upper_limit="46"/>
                    <measurement group_id="B2" value="45.5" lower_limit="27" upper_limit="61"/>
                    <measurement group_id="B3" value="43.9" lower_limit="26" upper_limit="63"/>
                    <measurement group_id="B4" value="53.3" lower_limit="51" upper_limit="57"/>
                    <measurement group_id="B5" value="43.8" lower_limit="27" upper_limit="56"/>
                    <measurement group_id="B6" value="50.1" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="B7" value="43.3" lower_limit="29" upper_limit="58"/>
                    <measurement group_id="B8" value="44.3" lower_limit="21" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Episodes of Diarrhea (Part A and Part B)</title>
        <description>Episodes of diarrhea is defined as the total number of stools with a Bristol Stool Chart (BSC) Score of 6 or 7 on day 3 of each treatment period. BSC is frequently used as a measure of consistency, and a score of 6 or 7 (pourable or watery stool) is considered abnormal.</description>
        <time_frame>24 hours on Day 3 of each treatment period</time_frame>
        <population>PD Analysis Set. All subjects with any available pharmacodynamic (PD) data and no major protocol deviations with impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: LIK066 + 50% CHO</title>
            <description>Part A: LIK066 + 50% carbohydrate CHO</description>
          </group>
          <group group_id="O2">
            <title>Part A: LIK066 + 25% CHO</title>
            <description>Part A: LIK066 + 25% carbohydrate CHO</description>
          </group>
          <group group_id="O3">
            <title>Part A: LIK066 + 0% CHO</title>
            <description>Part A: LIK066 + 0% carbohydrate CHO</description>
          </group>
          <group group_id="O4">
            <title>Part B: LIK066 + 50% CHO + NS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
          </group>
          <group group_id="O5">
            <title>Part B: LIK066 + 50% CHO + PS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
          </group>
          <group group_id="O6">
            <title>Part B: LIK066 + 50% CHO CC</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Diarrhea (Part A and Part B)</title>
          <description>Episodes of diarrhea is defined as the total number of stools with a Bristol Stool Chart (BSC) Score of 6 or 7 on day 3 of each treatment period. BSC is frequently used as a measure of consistency, and a score of 6 or 7 (pourable or watery stool) is considered abnormal.</description>
          <population>PD Analysis Set. All subjects with any available pharmacodynamic (PD) data and no major protocol deviations with impact on PD data.</population>
          <units>Number of stools</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.74"/>
                    <measurement group_id="O2" value="1.25" spread="1.42"/>
                    <measurement group_id="O3" value="0.38" spread="0.71"/>
                    <measurement group_id="O4" value="1.88" spread="1.51"/>
                    <measurement group_id="O5" value="1.46" spread="1.41"/>
                    <measurement group_id="O6" value="1.46" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.71</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.21</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.30</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.79</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.78</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.921</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.98</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Three-day Total Number of Episodes of Diarrhea (Part A and Part B)</title>
        <description>Episodes of diarrhea is defined as the total number of stools with a Bristol Stool Chart (BSC) Score of 6 or 7 on days 1 to 3 of each treatment period. BSC is frequently used as a measure of consistency, and a score of 6 or 7 (pourable or watery stool) is considered abnormal.</description>
        <time_frame>Day 1 to 3 of each treatment period</time_frame>
        <population>PD Analysis Set. All subjects with any available pharmacodynamic (PD) data and no major protocol deviations with impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: LIK066 + 50% CHO</title>
            <description>Part A: LIK066 + 50% carbohydrate CHO</description>
          </group>
          <group group_id="O2">
            <title>Part A: LIK066 + 25% CHO</title>
            <description>Part A: LIK066 + 25% carbohydrate CHO</description>
          </group>
          <group group_id="O3">
            <title>Part A: LIK066 + 0% CHO</title>
            <description>Part A: LIK066 + 0% carbohydrate CHO</description>
          </group>
          <group group_id="O4">
            <title>Part B: LIK066 + 50% CHO + NS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
          </group>
          <group group_id="O5">
            <title>Part B: LIK066 + 50% CHO + PS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
          </group>
          <group group_id="O6">
            <title>Part B: LIK066 + 50% CHO CC</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
          </group>
        </group_list>
        <measure>
          <title>Three-day Total Number of Episodes of Diarrhea (Part A and Part B)</title>
          <description>Episodes of diarrhea is defined as the total number of stools with a Bristol Stool Chart (BSC) Score of 6 or 7 on days 1 to 3 of each treatment period. BSC is frequently used as a measure of consistency, and a score of 6 or 7 (pourable or watery stool) is considered abnormal.</description>
          <population>PD Analysis Set. All subjects with any available pharmacodynamic (PD) data and no major protocol deviations with impact on PD data.</population>
          <units>Number of stools</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="3.01"/>
                    <measurement group_id="O2" value="2.83" spread="2.97"/>
                    <measurement group_id="O3" value="1.50" spread="2.02"/>
                    <measurement group_id="O4" value="4.42" spread="3.41"/>
                    <measurement group_id="O5" value="3.46" spread="3.24"/>
                    <measurement group_id="O6" value="4.00" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.68</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.54</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.141</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.79</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>0.90</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of number of events</param_type>
            <param_value>1.14</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Consistency With Bristol Stool Chart (Part A and Part B)</title>
        <description>BSC is frequently used as a measure of consistency, ranging from score 1 (hard lumps) to 7 (watery stool).</description>
        <time_frame>24 hours on Day 3 of each treatment period</time_frame>
        <population>PD Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: LIK066 + 50% CHO</title>
            <description>Part A: LIK066 + 50% carbohydrate CHO</description>
          </group>
          <group group_id="O2">
            <title>Part A: LIK066 + 25% CHO</title>
            <description>Part A: LIK066 + 25% carbohydrate CHO</description>
          </group>
          <group group_id="O3">
            <title>Part A: LIK066 + 0% CHO</title>
            <description>Part A: LIK066 + 0% carbohydrate CHO</description>
          </group>
          <group group_id="O4">
            <title>Part B: LIK066 + 50% CHO + NS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
          </group>
          <group group_id="O5">
            <title>Part B: LIK066 + 50% CHO + PS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
          </group>
          <group group_id="O6">
            <title>Part B: LIK066 + 50% CHO CC</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
          </group>
        </group_list>
        <measure>
          <title>Average Consistency With Bristol Stool Chart (Part A and Part B)</title>
          <description>BSC is frequently used as a measure of consistency, ranging from score 1 (hard lumps) to 7 (watery stool).</description>
          <population>PD Analysis Set.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="1.24"/>
                    <measurement group_id="O2" value="5.42" spread="1.42"/>
                    <measurement group_id="O3" value="4.71" spread="1.45"/>
                    <measurement group_id="O4" value="5.81" spread="1.07"/>
                    <measurement group_id="O5" value="5.52" spread="0.99"/>
                    <measurement group_id="O6" value="5.62" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.06</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.436</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.452</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Stool pH (Part A and Part B)</title>
        <description>Average PH of Stool at day 3</description>
        <time_frame>24 hours on Day 3 of each treatment period</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: LIK066 + 50% CHO</title>
            <description>Part A: LIK066 + 50% carbohydrate CHO</description>
          </group>
          <group group_id="O2">
            <title>Part A: LIK066 + 25% CHO</title>
            <description>Part A: LIK066 + 25% carbohydrate CHO</description>
          </group>
          <group group_id="O3">
            <title>Part A: LIK066 + 0% CHO</title>
            <description>Part A: LIK066 + 0% carbohydrate CHO</description>
          </group>
          <group group_id="O4">
            <title>Part B: LIK066 + 50% CHO + NS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
          </group>
          <group group_id="O5">
            <title>Part B: LIK066 + 50% CHO + PS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
          </group>
          <group group_id="O6">
            <title>Part B: LIK066 + 50% CHO CC</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
          </group>
        </group_list>
        <measure>
          <title>Average Stool pH (Part A and Part B)</title>
          <description>Average PH of Stool at day 3</description>
          <population>PD Analysis Set</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.44"/>
                    <measurement group_id="O2" value="6.50" spread="0.59"/>
                    <measurement group_id="O3" value="6.29" spread="0.23"/>
                    <measurement group_id="O4" value="6.52" spread="0.59"/>
                    <measurement group_id="O5" value="6.79" spread="0.67"/>
                    <measurement group_id="O6" value="6.66" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Stool Weight (Part A and Part B)</title>
        <description>24 hour average stool weight on day 3</description>
        <time_frame>24 hours on Day 3 of each treatment period</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: LIK066 + 50% CHO</title>
            <description>Part A: LIK066 + 50% carbohydrate CHO</description>
          </group>
          <group group_id="O2">
            <title>Part A: LIK066 + 25% CHO</title>
            <description>Part A: LIK066 + 25% carbohydrate CHO</description>
          </group>
          <group group_id="O3">
            <title>Part A: LIK066 + 0% CHO</title>
            <description>Part A: LIK066 + 0% carbohydrate CHO</description>
          </group>
          <group group_id="O4">
            <title>Part B: LIK066 + 50% CHO + NS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
          </group>
          <group group_id="O5">
            <title>Part B: LIK066 + 50% CHO + PS</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
          </group>
          <group group_id="O6">
            <title>Part B: LIK066 + 50% CHO CC</title>
            <description>Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
          </group>
        </group_list>
        <measure>
          <title>Average Stool Weight (Part A and Part B)</title>
          <description>24 hour average stool weight on day 3</description>
          <population>PD Analysis Set</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.5" spread="88.99"/>
                    <measurement group_id="O2" value="154.5" spread="87.11"/>
                    <measurement group_id="O3" value="116.7" spread="65.57"/>
                    <measurement group_id="O4" value="145.5" spread="75.21"/>
                    <measurement group_id="O5" value="177.1" spread="138.1"/>
                    <measurement group_id="O6" value="164.3" spread="108.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately22 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: LIK066 + 50% CHO</title>
          <description>Part A: LIK066 + 50% carbohydrate CHO</description>
        </group>
        <group group_id="E2">
          <title>Part A: LIK066 + 25% CHO</title>
          <description>Part A: LIK066 + 25% carbohydrate CHO</description>
        </group>
        <group group_id="E3">
          <title>Part A: LIK066 + 0% CHO</title>
          <description>Part A: LIK066 + 0% carbohydrate CHO</description>
        </group>
        <group group_id="E4">
          <title>Part A: LIK066 + 8% CHO</title>
          <description>Part A: LIK066 + 8% carbohydrate CHO</description>
        </group>
        <group group_id="E5">
          <title>Part B: LIK066 + 50% CHO + NS</title>
          <description>Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)</description>
        </group>
        <group group_id="E6">
          <title>Part B: LIK066 + 50% CHO + PS</title>
          <description>Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)</description>
        </group>
        <group group_id="E7">
          <title>Part B: LIK066 + 50% CHO CC</title>
          <description>Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

